Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious

Gene Therapy

Volumn 10, Issue 21, 2003, Pages 1800-1806

  Ebeling, S B ^a   Simonetti, E R ^a   Borst, H P E ^a   Blok, A ^b   Schelen, A M ^c   Braakman, E ^c   Ederveen, J ^b   Hagenbeek, A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MicroSafe BV   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical; Ex vivo transduction; Q PCR; Replication competent retrovirus; T lymphocytes

Indexed keywords

RETROVIRUS VECTOR; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL STRAIN 3T3; CELL TYPE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SAFETY; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION;

GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MOLONEY MURINE LEUKEMIA VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ANIMALIA; MOLONEY MURINE LEUKEMIA VIRUS; ONCOVIRINAE; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0141725691     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302080     Document Type: Article

References (27)

1. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
2. Chong H, Vile RG. Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Therapy 1996; 3: 624-629.
3. Chong H, Starkey W, Vile RG. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol 1998; 72: 2663-2670.
4. Cosset FL et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
5. Garrett E et al. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. Virology 2000; 266: 170-179.
6. Cornetta K et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther 1990; 1: 15-30.
7. Cornetta K et al. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum Gene Ther 1991; 2: 215-219.
8. Donahue RE et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-1135.
9. Vanin EF, Kaloss M, Broscius C, Nienhuis AW. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol 1994; 68: 4241-4250.
10. Purcell DF et al. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol 1996; 70: 887-897.
11. Miller AD, Law MT, Verma IM. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol 1985; 5: 431-437.
12. Weijtens M et al. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. Hum Gene Ther 2002; 13: 187-198.
13. Aboud M, Kimchi R, Bakhanashvili M, Salzberg S. Intracellular production of virus particles and viral components in NIH/3T3 cells chronically infected with Moloney murine leukemia virus: effect of interferon. J Virol 1981; 40: 830-838.
14. Paskind MP, Weinberg RA, Baltimore D. Dependence of Moloney murine leukemia virus production on cell growth. Virology 1975; 67: 242-248.
15. Harel J, Rassart E, Jolicoeur P. Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virology 1981; 110: 202-207.
16. Gloger I, Arad G, Panet A. Regulation of Moloney murine leukemia virus replication in chronically infected cells arrested at the G0/G1 phase. J Virol 1985; 54: 844-850.
17. Chen J et al. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Virology 2001; 282: 186-197.
18. Martineau D et al. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus. Hum Gene Ther 1997; 8: 1231-1241.
19. Wilson CA, Ng TH, Miller AE. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors. Hum Gene Ther 1997; 8: 869-874.
20. Cornetta K et al. Infection of human cells with murine amphotropic replication-competent retroviruses. Hum Gene Ther 1993; 4: 579-588.
21. Pitha PM. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 1994; 24: 205-219.
22. Barre-Sinoussi F et al. Enhancement of retrovirus production by anti-interferon serum. Ann Microbiol (Paris) 1979; 130B: 349-362.
23. Salzberg S et al. Characterization of intracellular viral RNA in interferon-treated cells chronically infected with murine leukemia virus. J Virol 1980; 35: 694-703.
24. Canaani E, Aaronson SA. Isolation and characterization of naturally occurring deletion mutants of Moloney murine sarcoma virus. Virology 1980; 105: 456-466.
25. Yoshimura FK, Yamamura JM. Four Moloney murine leukemia virus-infected rat cell clones producing replication-defective particles: protein and nucleic acid analyses. J Virol 1981; 38: 895-905.
26. Bassin RH et al. Normal DBA/2 mouse cells synthesize a glycoprotein which interferes with MCF virus infection. Virology 1982; 123: 139-151.
27. Van der Meide PH, Dubbeld M, Schellekens H. Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. 1985; 79: 293-305.